• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYInsights
  • MYBoard
  • Strategy & Consulting
Select Page

Understanding the Toxicity Profiles of Fat-Soluble Vitamins: Insights Into Vitamins A, D, E, and K

by MM360 Staff | May 20, 2025 | Myeloma News

Source: Pharmacy Times articles Health care professionals play a vital role in preventing overdose and ensuring safe use. Read More

A Pharmacist’s Guide to Diabetic Ketoacidosis

by MM360 Staff | May 20, 2025 | Myeloma News

Source: Pharmacy Times articles Diabetic ketoacidosis poses serious risks for patients with diabetes, requiring urgent treatment to prevent life-threatening complications and ensure recovery. Read More

Motivational Interviewing to Conquer Barriers for Diabetes Management

by MM360 Staff | May 20, 2025 | Myeloma News

Source: Pharmacy Times articles Motivational interviewing serves as a beneficial strategy to enhance medication adherence and improve patient outcomes in diabetes management. Read More

Linerixibat Significantly Improves PBC-Related Cholestatic Pruritus in Adult Patients

by MM360 Staff | May 20, 2025 | Myeloma News

Source: Pharmacy Times articles Compared with placebo, patients with cholestatic pruritus and primary biliary cholangitis (PBC) receiving linerixibat experienced improved itch and sleep interference. Read More

Self-Care for Women’s Health

by MM360 Staff | May 20, 2025 | Myeloma News

Source: Pharmacy Times articles Post Content Read More

Pharmacist Involvement in Clinical Research and the FINEARTS-HF Trial

by MM360 Staff | May 20, 2025 | Myeloma News

Source: Pharmacy Times articles Host Craig Beavers speaks with Orly Vardeny, PharmD, MS, a professor of medicine at the University of Minnesota Read More
« Older Entries
Next Entries »

Recent Content

  • Automated radiomics model for prediction of therapy response and minimal residual disease from baseline MRI in multiple myeloma
  • Prognostic and clinicopathological value of prognostic nutritional index in patients with multiple myeloma: a meta-analysis
  • Daratumumab plus lenalidomide maintenance in newly diagnosed multiple myeloma after transplant: AURIGA subgroup analyses
  • Randomized Phase 3 study of pomalidomide cyclophosphamide dexamethasone versus pomalidomide dexamethasone in relapse or refractory myeloma: an Asian Myeloma Network study (AMN003)
  • (no title)
  • The risk of second primary malignancies in patients receiving T-cell directed therapies for multiple myeloma: a systematic review
  • (no title)
  • Impact of residual clonal plasma cells in S-phase at the time of autologous stem cell transplantation on clinical outcomes
  • (no title)
  • Efficacy and toxicity of treatment of smoldering multiple myeloma: a systematic review and meta-analysis
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT